A rare mutation (p.Ala264Thr) of GATA4 is responsible for atrial septal defect and pulmonary valve stenosis Authors: Ai-Qian Zhang, Jie-Yi Long, Wei Xue, Rong Yu, Lei Zhu, Liang-Liang Fan Published: 2026 ABSTRACT Atrial septal defect (ASD) is a type of congenital heart defect characterized by the absence of atrial septal tissue. Research has shown that genetic factors play a significant role in the development of ASD. Variants in genes such as GATA binding protein 4 (GATA4), NK2 homeobox 5, and T-box transcription factor 5 have been identified in patients with ASD. In this study, we enrolled a Chinese family affected by ASD and PS. Whole exome sequencing and Sanger sequencing were used to investigate the genetic basis of lesions in this family. The AC16 cell line was used to perform the functional study. After data filtering and co-segregation analysis, we identified a rare mutation (NM_001308093.3: c.790G > A, p.Ala264Thr) in the GATA4 gene in the affected family members that was absent in the unaffected individuals. Bioinformatic analysis revealed that the newly identified mutation was deleterious and altered the hydrophobicity, size and polar of the GATA4 protein. Functional studies revealed that this rare mutation disrupted the stability of GATA4 and reduced the ability of GATA4 to activate the downstream target genes. Our findings highlight the importance of the N-terminal zinc finger structure of GATA4 in cardiac development. Additionally, our study contributes to the genetic diagnosis and counseling of families with congenital heart disease.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52332-x. Introduction Congenital heart defects (CHD) are the most common congenital anomalies in newborns, these defects present at birth and affect the structure or function of the heart1,2. These defects can include heart valve defects, atrial and ventricular septal defects, stenosis, and heart muscle abnormalities, which can pose significant clinical risks, including morbidity and mortality1. Atrial septal defect (ASD) is a type of congenital heart defect that occurs in 6–8 of 1000 live births3. ASD is defined as the absence or deficiency of atrial septal tissue, resulting in direct shunting of blood between the atria3,4. Patients with an ASD may not experience symptoms if the opening is small, but a large opening can cause permanent damage to the blood vessels of the lung because of the increased amount of blood being pumped into these vessels3. At present, the diagnosis of ASD is typically made through clinical evaluation, physical examination, electrocardiogram (ECG), chest X-ray, and echocardiography. Previous studies have demonstrated that patients with syndromic congenital heart defects, such as HIST1H1E syndrome (OMIM: 142220), McKusick–Kaufman syndrome (OMIM: 236700), and Holt–Oram syndrome (OMIM: 142900), can present with an ASD phenotype5. Moreover, ASD accounts for 25–30% of new cases with nonsyndromic congenital heart defects6,7. In recent years, an increasing number of families presenting with nonsyndromic ASD have been reported; these families have been subjected to genetic analysis, revealing lesions in several disease-related genes, including ZIC3, GATA4, NKX2.5, and MYH68,9. GATA4, a zinc finger GATA transcription factor family member that is one of the earliest factors expressed during cardiac development, plays an important role in the induction, formation, growth, and morphogenesis of the heart10,11. According to the Human Gene Mutation Database (www.hgmd.cf.ac.uk), 157 GATA4 mutations have been reported in cases of CHD, including conditions such as ASD and ventricular septal defect (VSD)12. In this study, we recruited a Chinese family affected by ASD and pulmonary valve stenosis (PS). Whole-exome sequencing, Sanger sequencing, and bioinformatics analysis were performed, and a rare mutation (NM_001308093.3: c.790G > A, p.Ala264Thr) in the GATA4 gene was identified in the affected family members. Functional studies conducted in the AC16 cell line provided additional evidence of the pathogenicity of this mutation. Materials and methods Subjects A 10-person, three-generation Chinese pedigree with ASD and PS was recruited in this study (Fig. 1A). Clinical data and peripheral blood samples were collected from five members, including three affected individuals (III-3, II-5, and II-1) and two unaffected individuals (I-2 and III-1).Fig. 1Whole exome sequencing identified a rare mutation of GATA4 in a family with ASD and PS. (A) The family pedigree figure. Squares indicate male members; circles, female members; closed symbols, affected members; open symbols, unaffected members; arrow, proband. (B) The data filtering strategy for whole exome sequencing in this study. (C) Sanger sequencing of GATA4 confirms the NM_001308093.3:c.790G > A (p.Ala264Thr) mutation in affected family members. (D) Alignment of multiple GATA4 protein sequences across species. The affected A264 amino acid is located in a highly conserved region in different mammals (from Ensembl). (E) Structure prediction of mutant protein. The wild-type GATA4 (WT) protein structure and the p.Ala264Thr mutant GATA4 protein structure are predicted using SWISS-MODEL online software. Whole exome sequencing identified a rare mutation of GATA4 in a family with ASD and PS. (A) The family pedigree figure. Squares indicate male members; circles, female members; closed symbols, affected members; open symbols, unaffected members; arrow, proband. (B) The data filtering strategy for whole exome sequencing in this study. (C) Sanger sequencing of GATA4 confirms the NM_001308093.3:c.790G > A (p.Ala264Thr) mutation in affected family members. (D) Alignment of multiple GATA4 protein sequences across species. The affected A264 amino acid is located in a highly conserved region in different mammals (from Ensembl). (E) Structure prediction of mutant protein. The wild-type GATA4 (WT) protein structure and the p.Ala264Thr mutant GATA4 protein structure are predicted using SWISS-MODEL online software. Mutation analysis Genomic DNA was extracted from peripheral blood lymphocytes of all enrolled individuals using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Whole-exome sequencing was performed to analyze the candidate genes of the proband (III-3). Agilent SureSelect Human All Exon V6 kits were used for exome capture, and high-throughput sequencing was conducted using the Illumina HiSeq X-10 platform. The BerryGenomic Institute (Beijing, China) provided support for the central part of the whole-exome sequencing, including targeted capture, massive parallel sequencing, reads mapping, variant detection, general data filtering, and annotation. The data filtering strategy was based on our previous studies13,14 and is shown in Fig. 1B. The filtered variants were validated and subjected to co-segregation analysis using Sanger sequencing. Primer pairs were designed using Primer 5 (the primer sequences can be provided upon request). Polymerase chain reaction (PCR) products were analyzed using the ABI 3100 Genetic Analyzer (ABI, Foster City, CA). The Swiss-Model software was utilized to predict the structure and potential effects of the mutation. Plasmid construction and cell culture The pEnter vector was engineered to include the wild-type (WT) GATA4 CDS with a C-terminal Flag-tag. The p.Ala264Thr-GATA4 missense mutation was introduced into this vector using the Takara MutanBEST Kit (Takara Bio, Japan). The pGL4.10 vector was engineered to include the human ANF promoter (from − 644 to + 35). The internal control reporter plasmid pRL-TK was purchased from Beyotime (Beijing). The AC16 cell line was purchased from the Cell Bank of the Shanghai Institutes for Biological Sciences (Shanghai, China) and cultured at 37 °C in a humidified incubator with a 5% CO2 atmosphere, using DMEM medium enriched with 10% fetal bovine serum, 50 IU/mL penicillin, 50 mmol/L streptomycin, and glutamine. Real-time PCR Total RNA was extracted by the PureLink® RNA Mini (Thermo Fisher Scientific, #12183025) from cells transfected with WT and mutated plasmids. cDNA was synthesized from a total of 1 μg of RNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, #K1621) with oligo (dT) primers. Real-time qPCR reactions were carried out in Fast 7500 Real-Time PCR Systems (Applied Biosystems) using Maxima SYBR Green/ROX qPCR Master Mix (2 ×) (Thermo Fisher Scientific, #K0221). And 2(−ΔΔCt) was used to compare transfected GATA4 mRNA expression. Western blot The GATA4-Flag-pEnter plasmids, both WT and mutated, were transfected into the AC16 cells for 36 h using Lipofectamine™ 2000 CD Transfection Reagent (Thermo Fisher Scientific, USA). Then, Cyclohexamide (CHX, 100 μg/mL, MedChemExpress, HY-12320) was added into the cells to assess the pathogenicity of the mutation via Western blot analysis. For the Western blot, cells were lysed on ice using RIPA buffer (Solarbio, China) and rotated for 2 h at 4 °C. The supernatant was obtained by centrifugation at 12,000 g for 30 min, and protein concentrations were determined using the BCA assay kit (Solarbio, China). Equal amounts of protein lysates were resolved on Bis–Tris NuPAGE gels (Solarbio, China), followed by standard Western blotting with antibodies against β-actin (#4967, Cell Signaling Technology, USA) and Flag (#86861S, Cell Signaling Technology, USA). Chemiluminescent signals were captured using a Tanon-5200 imaging system, exposure time was 10 s in this study. Protein expression levels were quantified using ImageJ software via grayscale densitometry analysis. Luciferase assay The AC16 cells were transfected with the ANF-pGL4.10 plasmid (200 ng), GATA4-Flag-pEnter plasmids (WT and mutated) (200 ng), as well as control reporter plasmid pRL-TK (5 ng) and cultured for 36 h. The luciferase activity of cells was measured by Dual-Lumi™ Luciferase Reporter Gene Assay Kit (Beyotime, Beijing) according to the manufacturer’s instructions. Three independent experiments were conducted in this study. Two-tailed Student’s t-tests and ANOVA were used for two-group comparisons. Statistical analysis Statistical analysis was performed using Graph-Pad Prism 8 (GraphPad Software). Results represent the mean ± SEM of at least 3 independent experiments. Two-tailed Student’s t-tests and ANOVA were used for two-group comparisons. Differences were considered statistically significant at p < 0.05. Results Clinical description of the family with ASD and PS A family from Hunan Province, comprising 10 members, participated in our study (Fig. 1A). The proband in this family was a 2-year-old male child (III-3), admitted to the hospital for acute onset of cough, productive sputum, and persistent fever lasting 24 h. Peak axillary temperature recorded was 38.9 °C. No associated respiratory distress (e.g., wheezing), gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, or diarrhea), or other systemic manifestations were reported. Physical examination in the outpatient department revealed a systolic murmur between the 2nd and 3rd ribs at the left sternal border. According to parental report, this murmur had not been previously identified. Laboratory evaluation revealed leukocytosis with a white blood cell count of 21.02 × 10⁹/L (neutrophils 75.0%, absolute neutrophil count 16.12 × 109/L; lymphocytes 14.7%, absolute lymphocyte count 3.11 × 109/L), hemoglobin 134 g/L, red blood cell count 4.52 × 1012/L, platelet count 302 × 109/L, and C-reactive protein 10.2 mg/L. Peripheral blood smear showed normal white blood cell morphology. Procalcitonin was elevated at 1.15 ng/mL. Serologic testing for Mycoplasma pneumoniae IgM and IgG antibodies yielded negative results. Immunoglobulin levels were within age-appropriate reference ranges: IgA 102.4 mg/dL, IgM 111.3 mg/dL, and IgG 1105.3 mg/dL. Cardiac biomarkers included myoglobin 8.42 ng/mL and N-terminal pro–B-type natriuretic peptide (NT-proBNP) 214.03 ng/L. B-ultrasound examination revealed a 7 mm ASD (hole II, central type), left-to-right atrial level shunt, right heart enlargement, moderate tricuspid regurgitation, and moderate PS. Among multiple heart lesions, PS and ASD represent the primary lesions. B-ultrasound reveals a characteristic dome-shaped morphology of the stenotic pulmonary valve, with a persistent transvalvular pressure gradient of 42 mmHg. Other lesions includiung right heart enlargement and tricuspid regurgitation are secondary changes (functional changes) caused by left-to-right shunting, rather than independent diseases. A thorough family history revealed that the child’s father (II-5) had been diagnosed with ASD at birth, and her aunt (II-2) had PS. The proband underwent successful surgical repair at the Department of Cardiothoracic Surgery of the Second Xiangya Hospital. Upon examination, no additional congenital abnormalities were detected in the proband or the other two affected family members (II-2 and II-5). This absence of associated malformations suggests that this family represents isolated or nonsyndromic congenital heart disease. Whole-exome sequencing identified a rare GATA4 mutation in the family Whole-exome sequencing identified 78,029 variants in the proband. Using the filtering method outlined in Fig. 1B, we selected 14 genetic variants, as detailed in Table 1. Validation through Sanger sequencing and cosegregation analysis revealed a rare mutation (NM_001308093.3: c.790G > A, p.Ala264Thr) in the GATA4 gene as a potential genetic lesion in this family (Fig. 1C). This mutation existed in gnomAD database (rs201520087, MAF = 0.00000744) and ClinVar database (VCV001057533.9) with a classification of uncertain significance. This mutation introduces a change from alanine to threonine at a site that is highly conserved across different species (Fig. 1D). Structural analysis indicated that the p.Ala264Thr mutation alters the hydrophobicity (with an index changing from + 1.8 to − 0.7), size and polar of GATA4 protein (template P43694.1.A, GMQE score 0.57), which could impact the protein’s structure and function (Fig. 1E). Bioinformatic softwires predicted that this mutation was deleterious (Table 2).Table 1Variants identified after data filtering in this study.ChrStartEndRBABGeneMutationOMIM125,746,70325,746,703GAMAN1C1NM_001289010.2:c.673G > A:p.D225N–2237,824,356237,824,356GARBM44NM_001080504.3:c.2386G > A:p.D796N–312,816,96812,816,968TGCAND2NM_001162499.2:c.2036 T > G:p.L679R–438,798,53138,798,531AGTLR1XM_024454198.1:c.301 T > C:p.S101PLeprosy670,294,18970,294,189TACOL9A1XM_017010246.2:c.125A > T:p.D42VAD, Epiphyseal dysplasia; AR, Stickler syndrome683,054,15183,054,151TGUBE3DNM_001304437.2:c.266A > C:p.D89A–811,750,11411,750,114GAGATA4NM_001308093.3:c.790G > A:p.A264TAD, congenital heart disease8130,951,994130,951,994CTADCY8NM_001115.3:c.1115G > A:p.R372Q–1097,679,69797,679,697GTAVPI1NM_021732.3:c.209C > A:p.A70D–1295,881,52895,881,528TCCCDC38XM_006719229.2:c.455A > G:p.D152G–12105,031,879105,031,879TCALDH1L2XM_011537986.2:c.1862A > G:p.H621R–1351,739,07251,739,072GTWDFY2XM_011534915.2:c.355G > T:p.D119Y–1461,280,10561,280,105TATMEM30BNM_001017970.3:c.1043A > T:p.D348V–1566,501,84966,501,849TARPL4NM_000968.4:c.485A > T:p.K162M–Chr: Chromosome, RB: Reference sequence base, AB: Alternative sequence base, AD: autosomal dominant, AR: autosomal recessive.Table 2In silico tool scores of the p.Ala264Thr mutation in GATA4.GeneVariantMutationTasterSIFTPolyphen-2CADDREVEL scorealpha-missenseGnomADGATA4c.790G > A, p.Ala264ThrDisease causing (0.9999)Damaging (0.048)POSSIBLY DAMAGING (0.584)23.50.569Likely pathogenic (0.592)0.00000744 Table 1Variants identified after data filtering in this study.ChrStartEndRBABGeneMutationOMIM125,746,70325,746,703GAMAN1C1NM_001289010.2:c.673G > A:p.D225N–2237,824,356237,824,356GARBM44NM_001080504.3:c.2386G > A:p.D796N–312,816,96812,816,968TGCAND2NM_001162499.2:c.2036 T > G:p.L679R–438,798,53138,798,531AGTLR1XM_024454198.1:c.301 T > C:p.S101PLeprosy670,294,18970,294,189TACOL9A1XM_017010246.2:c.125A > T:p.D42VAD, Epiphyseal dysplasia; AR, Stickler syndrome683,054,15183,054,151TGUBE3DNM_001304437.2:c.266A > C:p.D89A–811,750,11411,750,114GAGATA4NM_001308093.3:c.790G > A:p.A264TAD, congenital heart disease8130,951,994130,951,994CTADCY8NM_001115.3:c.1115G > A:p.R372Q–1097,679,69797,679,697GTAVPI1NM_021732.3:c.209C > A:p.A70D–1295,881,52895,881,528TCCCDC38XM_006719229.2:c.455A > G:p.D152G–12105,031,879105,031,879TCALDH1L2XM_011537986.2:c.1862A > G:p.H621R–1351,739,07251,739,072GTWDFY2XM_011534915.2:c.355G > T:p.D119Y–1461,280,10561,280,105TATMEM30BNM_001017970.3:c.1043A > T:p.D348V–1566,501,84966,501,849TARPL4NM_000968.4:c.485A > T:p.K162M–Chr: Chromosome, RB: Reference sequence base, AB: Alternative sequence base, AD: autosomal dominant, AR: autosomal recessive. Variants identified after data filtering in this study. Chr: Chromosome, RB: Reference sequence base, AB: Alternative sequence base, AD: autosomal dominant, AR: autosomal recessive. Table 2In silico tool scores of the p.Ala264Thr mutation in GATA4.GeneVariantMutationTasterSIFTPolyphen-2CADDREVEL scorealpha-missenseGnomADGATA4c.790G > A, p.Ala264ThrDisease causing (0.9999)Damaging (0.048)POSSIBLY DAMAGING (0.584)23.50.569Likely pathogenic (0.592)0.00000744 In silico tool scores of the p.Ala264Thr mutation in GATA4. The rare mutation disrupted GATA4 protein stability To determine the impact of the rare mutation, we constructed plasmids containing both the wild-type (WT) and mutant forms of GATA4 and transfected them into AC16 cells (Fig. 2A). Real-time PCR analysis showed that there were no differences between cells transfected with WT and mutated plasmids in mRNA levels (Fig. S1). Western blot analysis indicated a significant reduction in the expression of the transfected GATA4 (Flag) protein in the mutant group compared with the WT group (Fig. 2B). Cyclohexamide (CHX) was administered to the cells after transfection with the plasmids and Western blot analysis revealed that the rate of degradation of the transfected GATA4 (Flag) protein in the mutant group was faster than that in the WT group (Fig. 2C, D). Next, we performed Dual-Lumi™ luciferase reporter gene assay to assess the transactivation effect of this mutation. Plasmid transfection concentrations were normalized prior to the dual-luciferase assay based on quantitative Western blot analysis of corresponding protein expression. And the Dual-Lumi™ luciferase reporter gene assay showed that the cells transfected with GATA4-Flag-pEnter (p.Ala264Thr) exhibited a crucial reduced transactivation of the ANF promoter (P < 0.01) compared to the cells transfected with GATA4-Flag-pEnter (WT) (Fig. 2E). These functional studies suggest that the rare mutation (p.Ala264Thr) likely impairs the stability of the GATA4 protein and reduces the ability of GATA4 to activate the downstream target gene. According to the American College of Medical Genetics and Genomics (ACMG) guidelines, the mutation is classified as pathogenic: PS3 (established in vitro functional studies supportive of damaging effect on the gene) + PM2 ( with extremely low MAF in control databases) + PM5 (Missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before) + PP1 (Co-segregation analysis) + PP3 (Computational evidence support a deleterious effect on the gene).Fig. 2Functional studies revealed that the rare mutation disrupted the GATA4 protein stability. (A) Sanger sequencing validates the construction of the mutated GATA4 plasmid. The arrows mark the changed nucleobases. (B) Western blot detects the expression of transfected GATA4 (Flag) in the WT and GATA4-mutated groups. (C) Grayscale statistics of B. (D) Western blot shows the degradation rate of transfected GATA4 (Flag) in the WT and mutated groups after CHX treatment. (E) Grayscale statistics of D. (F) Luciferase reporter gene assay shows significantly reduced transcriptional activity of the p.Ala264Thr mutated GATA4 protein. Functional studies revealed that the rare mutation disrupted the GATA4 protein stability. (A) Sanger sequencing validates the construction of the mutated GATA4 plasmid. The arrows mark the changed nucleobases. (B) Western blot detects the expression of transfected GATA4 (Flag) in the WT and GATA4-mutated groups. (C) Grayscale statistics of B. (D) Western blot shows the degradation rate of transfected GATA4 (Flag) in the WT and mutated groups after CHX treatment. (E) Grayscale statistics of D. (F) Luciferase reporter gene assay shows significantly reduced transcriptional activity of the p.Ala264Thr mutated GATA4 protein. Discussion GATA4, a transcription factor with high evolutionary conservation, was initially identified for its role in mediating gene expression changes associated with cardiac hypertrophy15. Further studies in mice have shown that Gata4 is expressed in various adult tissues, including the heart, gut epithelium, and gonads16. During fetal development, Gata4 expression is observed in the yolk sac endoderm and cells that are critical for heart formation17. In 2003, Garg et al. reported that GATA4 mutations were linked to ASD18. They also discovered that GATA4 interacts with T-box transcription factor 5 (TBX5) and NKX2.5 to form a complex that can regulate a subset of genes that is essential for cardiac septal formation18. Recent research has confirmed that variations in TBX5 and NKX2.5 can also result in congenital heart disease8. Since their initial discovery, mutations in GATA4 have been associated with a range of congenital heart diseases, including VSD, tetralogy of Fallot, and PS19,20. In addition, several studies have reported that variants of GATA4 can cause dilated cardiomyopathy and atrial fibrillation21,22. A review of the literature indicates that over 60 individuals with ASD have been identified as GATA4 mutation carriers. In this study, we identified a rare GATA4 mutation (NM_001308093.3: c.790G > A, p.Ala264Thr) in a patient with ASD and PS. Our study provides additional data to explore the correlation between GATA4 mutations and different phenotypes of congenital heart disease. The GATA4 protein contains two transcription activation domains, zinc finger structures at the C-terminus and N-terminus, and nuclear localization signals23. The zinc finger structures at the C- and N-termini are coordinated by four cysteine residues and zinc atoms, forming two β-folds and an α-helix protein domain24. The C-terminal zinc finger domain primarily mediates most of the cooperative interactions, whereas the stable N-terminal domain is mainly responsible for physical interactions and gene blockade25,26. In this study, the p.Ala264Thr mutation of GATA4 was found in the N-terminal zinc finger structure. Functional studies revealed that the p.Ala264Thr mutation may reduce protein stability of GATA4 and reduce the ability of GATA4 to activate the downstream target genes, such as ANF in this study. Therefore, the rare GATA4 mutation (NM_001308093.3: c.790G > A, p.Ala264Thr) identified in this study can further disrupt the transcription of downstream genes related to heart development, resulting in ASD and PS. The p.Ala264Thr mutation of GATA4 is located in a mutational hotspot region. Previous studies have revealed that the p.A264G mutation of GATA4 was identified in patients with coronary heart disease and VSD27. Simultaneously, other germline mutations, such as p.R260Q and p.L261P, of GATA4 were detected in patients with ASD28. In addition, this mutation was also recorded in ClinVar (VCV001057533.9) and the phenotypes were ASD and cardiovascular malformation. Although this mutation existed in gnomAD (rs201520087), the MAF of the mutation in gnomAD was extremely low (0.00000744). Considering the functional studies in this study and other evidence including the bioinformatic prediction and c-segregation analysis, we believed that this mutation was pathogenic. ogether with other studies, our study confirms that the N-terminal zinc finger structure of GATA4, including the p.264 site, is important for cardiac development. This finding is consistent with studies in Gata4-knockout mice, which showed that inactivation of GATA4 can lead to incomplete myocardial development and the occurrence of congenital heart diseases, including ASD, VSD, and PS29. Conclusion In conclusion, we utilized whole exome sequencing and Sanger sequencing to discover a rare GATA4 mutation (NM_001308093.3: c.790G > A, p.Ala264Thr) in a Chinese family affected by ASD and PS. Functional studies demonstrated that this new mutation can reduce protein stability of GATA4 and reduce the ability of GATA4 to activate the downstream target genes. Our study confirmed the pathogenicity of the mutation and proved the importance of the N-terminal zinc finger structure of GATA4 in cardiac development. The identification of the pathogenic mutation in GATA4 may also contribute to the genetic diagnosis and counseling of families with congenital heart disease. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2